By Ana Espino | Published on April 17, 2026 | 3 min read
Chagas disease is a parasitic infection caused by Trypanosoma
cruzi, affecting approximately 6–7 million people worldwide, mainly in
Latin America. It is characterized by an acute phase followed by a chronic
infection that can last a lifetime and, in about 30% of patients, progress to
severe cardiac or digestive complications.
Current treatment options are limited to two drugs,
benznidazole and nifurtimox, whose effectiveness is mainly demonstrated during
the acute phase. Their efficacy declines significantly in the chronic phase,
and their use is often limited by adverse effects. Moreover, no vaccine is
currently available, representing a major gap in the fight against this
disease.
There are numerous challenges: high genetic diversity of the
parasite, complexity of the immune response, immune evasion mechanisms, and
difficulties in translating preclinical findings into humans. These factors
greatly complicate the development of an effective vaccine.
In this context, this study, recently published in The
Lancet, was conducted to review scientific and technological advances in
the development of a vaccine against Chagas disease.
Can an effective vaccine finally be developed ?
The article is based on a review of preclinical and
translational data regarding:
• the mechanisms of the immune response to T. cruzi,
• the genetic and biological diversity of the parasite,
• the different vaccine strategies under development (attenuated parasites,
recombinant proteins, DNA and mRNA vaccines).
The data show that the immune response plays a central role
in controlling infection. A Th1-type response, involving CD4+ and CD8+ T
lymphocytes and the production of IFN-γ, is essential for limiting parasitemia.
However, excessive inflammatory responses can contribute to tissue damage,
particularly in the heart. The parasite also possesses sophisticated immune
evasion mechanisms, notably through variability in its surface antigens, which
complicates the development of universal vaccines.
Several vaccine strategies have been explored:
• attenuated parasites, capable of inducing strong immunity but raising safety
concerns,
• recombinant protein vaccines, targeting key antigens and showing promising
preclinical results,
• DNA vaccines and viral vectors, inducing robust immune responses,
• mRNA vaccines, inspired by recent advances, with encouraging results in
animal models.
The article also highlights different potential uses of
vaccination:
• prophylactic (prevention of infection),
• therapeutic (improving treatment efficacy and disease control),
• or combined with chemotherapy to enhance parasitological cure.
However, many challenges remain, particularly in clinical
trial design, selection of target populations, and identification of relevant
biomarkers to assess vaccine efficacy.
A hope yet to be realized
Chagas disease remains a complex chronic condition,
difficult to treat and lacking an effective preventive strategy. The main
challenges in its management relate to parasite diversity, immune evasion
mechanisms, and barriers to clinical translation of vaccine candidates.
This study aimed to evaluate progress in developing a
vaccine against Chagas disease and to identify the most promising strategies.
The results show that, despite significant advances in understanding immune
mechanisms and in developing new vaccine platforms, no vaccine is yet
available. Nevertheless, combined therapeutic approaches—particularly those
associating vaccination with drug treatment—appear especially promising.
Chagas disease remains a complex chronic condition,
difficult to treat and lacking an effective preventive strategy. The main
challenges in its management relate to parasite diversity, immune evasion
mechanisms, and barriers to clinical translation of vaccine candidates.
This study aimed to evaluate progress in developing a
vaccine against Chagas disease and to identify the most promising strategies.
The results show that, despite significant advances in understanding immune
mechanisms and in developing new vaccine platforms, no vaccine is yet
available. Nevertheless, combined therapeutic approaches—particularly those
associating vaccination with drug treatment—appear especially promising.
Read next: Zika:
A Latent Threat or a Past Danger?
About
the author –
Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap
between research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and accessible.
Her mission: to accelerate knowledge sharing and empower evidence-based
decisions through impactful communication.
